Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more) Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Edgewise Therapeutics Inc EWTX

Healthcare Biotechnology
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company... see more

Recent & Breaking News (NDAQ:EWTX)

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PR Newswire December 2, 2025

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

PR Newswire November 20, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PR Newswire November 12, 2025

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

PR Newswire November 10, 2025

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

PR Newswire November 7, 2025

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

PR Newswire November 6, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PR Newswire November 3, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PR Newswire October 2, 2025

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

PR Newswire October 2, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PR Newswire September 3, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

ACCESS Newswire August 19, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

ACCESS Newswire August 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

GlobeNewswire August 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

PR Newswire August 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

ACCESS Newswire August 15, 2025

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire August 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

ACCESS Newswire August 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

GlobeNewswire August 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

ACCESS Newswire August 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

PR Newswire August 11, 2025

Podcasts